MVF: Trading update reveals volumes and earnings remain under pressure

Research evidence excerpt

MVF: Trading update reveals volumes and earnings remain under pressure

Monash IVF Group Limited

Key sustainability questions

This section is intended to highlight key sustainability discussion points relevant to this company, as well as our views on the outlook. Both the

questions we highlight and our responses will evolve over time as the dialogue between management, analysts and investors continues to

advance. We welcome any feedback on the topics.

Our view

What are the most material The ARS industry affects the environment via its laboratory and clinical operations.

sustainability issues facing this Medical supplies including single-use plastics, stainless steel oocyte retrieval needles

company? and discarded human embryos in clinics and laboratories result in landfill and

medical waste. Laboratories and clinical patient care flows still involve paper usage.

Transporting frozen reproductive cells and tissues, cylinders and tanks of specialty

gases and liquid nitrogen for incubators, cryopreservation and cryostorage across

cities is carbon-footprint heavy. The advancement and use of ART has raised complex

ethical and societal concerns related to acceptable practices, inequitable access to

care, surrogacy and gestational carrier use and an individual’s right to their genetic

offspring.

Does the company integrate In FY23, MVF started to explore environmentally responsible strategies including

sustainability considerations into its packaging minimisation and recycling optimisation for consumables, repurposing

strategy? obsolete or unwanted equipment and a strategy aimed at reducing landfill

waste per patient episode. One of MVF’s ‘Digital Transformation’ projects was to

review patient care flows and the ability to digitise this process to reduce paper

waste.